ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Improving response evaluation in oncology trials"
Episode Synopsis
RECIST expert Dr. Oliver Bohnsack discusses a recent study that demonstrated the survival benefit to a subgroup of patients when irRECIST is used instead of RECIST 1.1 for image assessment in solid tumor trials, as irRECIST takes the entire tumor burden, including new tumor growth, into consideration.
More episodes of the podcast Calyx Cafe
Three Ingredients to Successful Partnerships
27/10/2022
Craig Mooney: Data, Data, Who Owns the Data?
09/08/2022
Physician-centricity
22/09/2022
No Such Thing as "Clone and Go"
09/08/2022
In God we trust